The European Commission says it plans to produce a set of concrete measures to address the supply chain issues that can lead to drug shortages in the EU by the end of this year, under what it calls a “structured dialogue” with stakeholders from the pharmaceutical industry and patient and health professional organizations.
EU Launches ‘Structured Dialog’ To Thrash Out Supply Chain Concerns
First Meeting Slated For 25 March
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
More from Europe
• By
EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.
• By
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
• By
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
• By
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
More from Geography
• By
EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.
• By
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
• By
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.